Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Cystic Fibrosis
Lumacaftor-Ivacaftor Improves Lung Function in Cystic Fibrosis After 1 Year
After one year of therapy, patients had improved lung function, increased BMI, and a reduced need for intravenous antibiotics.
New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis
A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.
Comparing Efficacy of Once vs Thrice Daily Aminoglycosides in Cystic Fibrosis
Once- and thrice-daily treatment with aminoglycosides appear to be equally effective for reducing pulmonary exacerbations in cystic fibrosis.
FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combination for Cystic Fibrosis
The FDA has accepted for priority review the NDA for elexacaftor, tezacaftor and ivacaftor triple combination regimen for patients with cystic fibrosis.
The Limits of Antimicrobial Sensitivity Testing in Cystic Fibrosis
Management of infection in cystic fibrosis is complex but plays a critical role in improving the survival of those with CF.
Novel Triple Combination Therapy for Cystic Fibrosis Submitted for FDA Review
The NDA for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA.
Key Cystic Fibrosis Pathogens Reduced With Ivacaftor
Ivacaftor use was linked to reductions in P. aeruginosa rates, prevalence of S. aureus, Aspergillus species.
Palivizumab Not Associated With Improved Long-Term Outcomes in Cystic Fibrosis
Treatment with palivizumab was not associated with improved long-term outcomes in children with cystic fibrosis.
Ivacaftor Safe in Cystic Fibrosis With Non-G551D Gating Mutations
Ivacaftor is safe and effective in patients with cystic fibrosis who have severe lung disease and non-G551D gating mutations.
Next post in Obstructive Lung Disease
